NeuroPace is a U.S.-based medical device manufacturer that specializes in implantable neurostimulation technology for patients with drug-resistant focal epilepsy. The company's primary product, the RNS System, is surgically implanted near the seizure origin and automatically delivers targeted stimulation when abnormal electrical activity is detected. NeuroPace also offers supporting software tools for physicians to program devices and monitor patient outcomes, along with a data management platform that tracks information recorded by the implanted systems.
1Y: 7.56 (-41.6%) · range 7.56–19.29
entry readiness 85 · STRONG SETUP · exit proximity 0
Value area 12.36–17.21 · 77% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Nov 13, 2026 |
Not yet labeled — the study prices these as positions mature.